Management of Chemotherapy-Induced Cardiotoxicity

Introduction to Cardiotoxicity

The management of chemotherapy-induced cardiotoxicity requires early detection, prompt intervention with ACE inhibitors and beta-blockers, and careful monitoring of cardiac function throughout treatment and follow-up, as recommended by the European Society of Medical Oncology 1, 2

Comprehensive cardiovascular risk assessment before initiating potentially cardiotoxic chemotherapy is mandatory, including assessment of cardiac structure, performance, and hemodynamics, as suggested by the European Society of Cardiology 4
Serial monitoring of cardiac function at baseline, 3, 6, and 9 months during treatment, and at 12 and 18 months after initiation, is recommended by the American Heart Association 1
Cardiac biomarkers, such as troponin I and BNP, should be measured at baseline and periodically during therapy to identify patients at risk of cardiotoxicity, according to the American College of Cardiology 1, 2

For LVEF decline to <50% during anthracycline treatment, reassess after 3 weeks, hold chemotherapy if confirmed, and consider therapy for LVD, as recommended by the National Comprehensive Cancer Network 1
For LVEF decline to <40%, stop chemotherapy, discuss alternative treatments, and initiate heart failure therapy, according to the European Society of Medical Oncology 1

All patients with symptomatic LVD and LVEF <40% should be treated with an ACE inhibitor in combination with a beta-blocker, as recommended by the American College of Cardiology 1, 2
Early intervention is critical, with treatment initiated within 2 months from the end of chemotherapy having a higher likelihood of complete LVEF recovery, according to the American Heart Association 5

Use of liposome-encapsulated doxorubicin for patients at high risk of cardiotoxicity is recommended by the European Society of Medical Oncology 6
Consider cardioprotective regimens, including dexrazoxane, beta-blockers, and ACE inhibitors or angiotensin receptor blockers, as suggested by the American College of Cardiology 2, 6

Increased vigilance is recommended for patients ≥60 years old due to limited data in elderly populations, according to the National Institute on Aging 1
Long-term follow-up is essential, with assessment of cardiac function recommended 4 and 10 years after anthracycline therapy in patients treated at <15 years of age or with high cumulative doses, as recommended by the Children's Oncology Group 1

Continued cardiac monitoring after completion of therapy, especially for patients who received anthracyclines, is recommended by the American Heart Association 1
Novel imaging techniques like 3D echocardiography and strain rate imaging show promise in detecting early subclinical changes in cardiac performance, according to the European Association of Cardiovascular Imaging 5